Hematologic Oncology

Latest News

July 17th 2020

Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

By Paul J. Shaughnessy, MD

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

July 17th 2020

Ongoing Trial Evaluates Zanubrutinib in BTK-Intolerant B-Cell Malignancies

By Jessica Hergert

July 17th 2020

Expert Confirms Efficacy, Safety in Final ASCEND Data With Acalabrutinib in Relapsed/Refractory CLL

By Kristi Rosa

July 17th 2020

Liso-Cel Takes Step Toward EU Approval in B-Cell Lymphomas

By Kristi Rosa

July 17th 2020

Future of BCMA-Targeted Therapies in Multiple Myeloma

By Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital, Natalie S. Callander, MD, University of Washington Carbone Cancer Center , Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Latest Videos

Molecular Testing for Acute Myeloid Leukemia

David Sallman, MD, of Moffitt Cancer Center

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

Dr. Pollyea on Emerging Therapies in Higher-Risk Myelodysplastic Syndrome

$Relapsed/Refractory DLBCL: Sequencing Therapy$

Relapsed/Refractory DLBCL: Sequencing Therapy

$Safety of Loncastuximab Tesirine for Relapsed/Refractory DLBCL$

Safety of Loncastuximab Tesirine for Relapsed/Refractory DLBCL

Bone Marrow Transplant for Patients With MF

Outlook for CNS Lymphoma

DLBCL: Approaching CNS Prophylaxis

Dr. Atallah on the Clinical Implications of the QUAZAR AML-001 Trial in AML

The Impact of Mutational Status on Treatment Considerations for MDS

CME Content

Virtual Event

Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist's Evolving Role

October 29, 2026

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Wisconsin Association of Hematology and Oncology

Virginia Kaklamani, MD, DSc; Girish Kunapareddy, MD

Virtual Event

New Mexico Society of Clinical Oncology

1 Session is Available!

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Wyoming State Oncology Society & Montana State Oncology Society

Sarah M. Tolaney, MD, MPH; Yelda Nouri, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Indiana Oncology Society

Geoffrey Ku, MD; Girish Kunapareddy, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Rhode Island Oncology Society

Shiven Patel, MD, MBA, FACP; Sunnie S. Kim, MD

Virtual Event

Colorado Oncology Society

1 Session is Available!

Video

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors – Kansas Society of Clinical Oncology

Mrinal M. Gounder, MD; Madhuri Yalamanchili, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | New Mexico Society of Clinical Oncology

Benjamin Scheier, MD; Syma Iqbal, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Iowa Oncology Society

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Virtual Event

Rhode Island Oncology Society

1 Session is Available!

In-Person + Virtual Event

44th Annual CFS®: Innovative Cancer Therapy for Tomorrow™

November 11-13, 2026

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Minnesota Society of Clinical Oncology

Kate Baxstrom, MD; Virginia Kaklamani, MD, DSc

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Empire State Hematology and Oncology Society

Jack W. Erter III, MD, MMHC; Geoffrey Ku, MD

Video

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Frantz Francisque, MD; Jacob Sands, MD

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Komal Jhaveri, MD, FACP; Ruta D. Rao, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Kentucky Society of Clinical Oncology

Sunnie S. Kim, MD; Jack W. Erter III, MD, MMHC

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | South Carolina Oncology Society

Geoffrey Ku, MD; Shiven B. Patel, MD, MBA, FACP

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Texas Society of Clinical Oncology

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Virtual Event

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Webinar Series

Virtual Event

Tennessee Oncology Practice Society

1 Session is Available!

Video

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Jacob Sands, MD; Shiven B. Patel, MD, MBA, FACP

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

Virtual Event

South Carolina Oncology Society

1 Session is Available!

Virtual Event

Texas Society of Clinical Oncology

1 Session is Available!

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Video

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Video

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Amy E. Armstrong, MD; Anu Batra, MD

Video

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Daniela A. Bota, MD, PhD; Shiven Patel, MD, MBA

Video

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Daniela A. Bota, MD, PhD; Maya Hrachova, DO

Virtual Event

Washington State Medical Oncology Society

2 Sessions are Available!

Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Virtual Event

Wyoming State Oncology Society

2 Sessions are Available!

Virtual Event

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Virtual Event

Wisconsin Association of Hematology and Oncology

3 Sessions are Available!

Virtual Event

Minnesota Society of Clinical Oncology

1 Session is Available!

Video

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Virtual Event

Arizona Clinical Oncology Society

1 Session is Available!

Video

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Virtual Event

Nevada Oncology Society

3 Sessions are Available!

Virtual Event

Missouri Oncology Society

2 Sessions are Available!

Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Video

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Video

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, MBA, FACP

Video

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD; Jonathan Strosberg, MD

Video

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Eunice Wang, MD; Hetty Carraway, MD, MBA; Naval G. Daver, MD

More News

Bispecific Antibodies for Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Novel Therapies: R2-GDP-GOTEL and Smart Start

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

SADAL Trial Regimen FDA Approval

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Overview

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

CAR T-Cell Therapy Clinical Trials

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

CAR T-Cell Therapy Response Rates

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

MRD Monitoring in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

The Role of Transplant in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020